Findings

What do systematic reviews say?

16 questions · 16 findings · 4 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 7 · 43.8%GRADE not reported 0 · 0%Very low 0 · 0%Low 7 · 43.8%Moderate 2 · 12.5%High 0 · 0%

Long‐term red cell transfusion vs no transfusion

Quality of life · individuals with sickle cell disease who are at risk of a primary stroke who have not had previous long‐term red cell transfusions

1 finding from 1 review

Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 196 participants
Low

Long‐term red cell transfusion vs no transfusion

Quality of life ‐ not reported · individuals with sickle cell disease who are at risk of a primary stroke who have had long‐term red cell transfusions to prevent a stroke

The review found no eligible studies for this question.

1 finding from 1 review

Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Long‐term red cell transfusion vs hydroxyurea and phlebotomy

Quality of life ‐ not reported · individuals with sickle cell disease who are at risk of a primary stroke who have had long‐term red cell transfusions to prevent a stroke

The review found no eligible studies for this question.

1 finding from 1 review

Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Long‐term red cell transfusion vs hydroxyurea and phlebotomy

Quality of life ‐ not reported · individuals with sickle cell disease who have had a stroke who have had long‐term red cell transfusions to prevent another stroke

The review found no eligible studies for this question.

1 finding from 1 review

Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Long‐term red cell transfusion vs usual care

Quality of life · prevention of SCI in people with SCD and normal TCD velocities

1 finding from 1 review

Interventions for preventing silent cerebral infarcts in people with sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 196 participants
Low

Long‐term red cell transfusion vs usual care

Quality of life ‐ not reported · prevention of SCI in people with SCD and abnormal TCD velocities

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing silent cerebral infarcts in people with sickle cell disease 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: inhaled TOBI® (IV preparation) vs tobramycin

Quality of life · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

The review found no eligible studies for this question.

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: tobramycin for inhalation powder vs tobramycin

Quality of life · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

The review found no eligible studies for this question.

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: anti‐pseudomonal antibiotics vs placebo

Quality of life: lost school or working days · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 245 participants
Low

Summary of findings: levofloxacin for inhalation solution vs tobramycin

Quality of life: change from baseline in CFQ‐R · adults and children aged over 12 with CF and P aeruginosa

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 282 participants
Low

Summary of findings: amikacin liposome inhalation suspension (ALIS) vs tobramycin

QoL · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 294 participants
Moderate

Beta‐2 agonists vs placebo

Participant‐reported outcomes: quality of life (measured by CFQ‐R) · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Long‐acting inhaled bronchodilators for cystic fibrosis 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

LAMA vs placebo

Participant‐reported outcomes: quality of life (measured by CFQ‐R) · adults and children with cystic fibrosis

1 finding from 1 review

Long‐acting inhaled bronchodilators for cystic fibrosis 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 974 participants
Low

Summary of findings: colistimethate dry powder for inhalation (Colobreathe®) vs tobramycin

QoL · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 374 participants
Low

Summary of findings: continuous cycles alternating aztreonam lysine for inhalation with tobramycin for inhalation solution vs continuous cycles alternating placebo with tobramycin

Quality of life: respiratory domain · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 90 participants
Low

Summary of findings: aztreonam lysine for inhalation vs tobramycin

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 268 participants
Moderate